Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Report

Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-695-0
Number of Pages: 120
Format: Electronic (PDF)

Historical Range: 2018 - 2022
Industry: Healthcare

Market Segmentation

Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
- Adenovirus
- Retrovirus
- Adeno-Associated Virus (AAV)
- Lentivirus
- Plasmids
- Others
Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
- Upstream Manufacturing
  - Vector Amplification & Expansion
  - Vector Recovery/Harvesting
- Downstream Manufacturing
  - Purification
  - Fill Finish
Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
- Antisense & RNAi Therapy
- Gene Therapy
- Cell Therapy
- Vaccinology
- Research Applications
Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Viral Vectors And Plasmid DNA Manufacturing Regional Outlook (Revenue, USD 2018 - 2030)
- North America
  - North America Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Plasmids
    - Others
  - North America Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    - Upstream Manufacturing
      - Vector Amplification & Expansion
      - Vector Recovery/Harvesting
    - Downstream Manufacturing
      - Purification
      - Fill Finish
  - North America Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Antisense & RNAi Therapy
    - Gene Therapy
    - Cell Therapy
    - Vaccinology
    - Research Applications
  - North America Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Research Institutes
  - North America Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    - Cancer
    - Genetic Disorders
    - Infectious Diseases
    - Others
  - U.S.
    - U.S. Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - U.S. Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - U.S. Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Antisense & RNAi Therapy
      - Gene Therapy
      - Cell Therapy
      - Vaccinology
      - Research Applications
    - U.S. Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - U.S. Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Canada
    - Canada Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Canada Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Canada Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Antisense & RNAi Therapy
      - Gene Therapy
      - Cell Therapy
      - Vaccinology
      - Research Applications
    - Canada Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Canada Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
- Europe
  - Europe Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Plasmids
    - Others
  - Europe Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    - Upstream Manufacturing
      - Vector Amplification & Expansion
      - Vector Recovery/Harvesting
    - Downstream Manufacturing
      - Purification
      - Fill Finish
  - Europe Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
  - Europe Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Research Institutes
  - Europe Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    - Cancer
    - Genetic Disorders
    - Infectious Diseases
    - Others
  - Germany
    - Germany Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Germany Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Germany Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Germany Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Germany Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - U.K.
    - U.K. Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - U.K. Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - U.K. Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - U.K. Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - U.K. Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - France
    - France Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - France Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - France Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - France Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - France Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Spain
    - Spain Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Spain Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Spain Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Spain Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Spain Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Italy
    - Italy Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Italy Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Italy Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Italy Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Italy Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Denmark
    - Denmark Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Denmark Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Denmark Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Denmark Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Denmark Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Sweden
    - Sweden Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Sweden Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Sweden Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Sweden Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Sweden Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Norway
    - Norway Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Norway Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Norway Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Norway Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Norway Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
- Asia Pacific
  - Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Plasmids
    - Others
  - Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    - Upstream Manufacturing
      - Vector Amplification & Expansion
      - Vector Recovery/Harvesting
    - Downstream Manufacturing
      - Purification
      - Fill Finish
  - Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
  - Asia Pacific Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Research Institutes
  - Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    - Cancer
    - Genetic Disorders
    - Infectious Diseases
    - Others
  - Japan
    - Japan Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Japan Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Japan Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Japan Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Japan Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - China
    - China Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - China Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - China Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - China Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - China Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - India
    - India Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - India Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - India Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - India Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Indiaa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Thailand
    - Thailand Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Thailand Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Thailand Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Thailand Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Thailand Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - South Korea
    - South Korea Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - South Korea Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - South Korea Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - South Korea Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - South Korea Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Australia
    - Australia Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Australia Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Australia Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Australia Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Australia Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
- Latin America
  - Latin America Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Plasmids
    - Others
  - Latin America Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    - Upstream Manufacturing
      - Vector Amplification & Expansion
      - Vector Recovery/Harvesting
    - Downstream Manufacturing
      - Purification
      - Fill Finish
  - Latin America Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
  - Latin America Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Research Institutes
  - Latin America Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    - Cancer
    - Genetic Disorders
    - Infectious Diseases
    - Others
  - Brazil
    - Brazil Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Brazil Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Brazil Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Brazil Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Brazil Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Mexico
    - Mexico Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Mexico Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Mexico Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Mexico Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Mexico Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Argentina
    - Argentina Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Argentina Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Argentina Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Argentina Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Argentina Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
- MEA
  - MEA Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Plasmids
    - Others
  - MEA Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    - Upstream Manufacturing
      - Vector Amplification & Expansion
      - Vector Recovery/Harvesting
    - Downstream Manufacturing
      - Purification
      - Fill Finish
  - MEA Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
  - MEA Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Pharmaceutical and Biopharmaceutical Companies
    - Research Institutes
  - MEA Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    - Cancer
    - Genetic Disorders
    - Infectious Diseases
    - Others
  - South Africa
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - South Africa Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Saudi Arabia
    - Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Antisense & RNAi Therapy
      - Gene Therapy
      - Cell Therapy
      - Vaccinology
      - Research Applications
    - South Africa Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - South Africa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - UAE
    - UAE Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - UAE Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - UAE Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Antisense & RNAi Therapy
      - Gene Therapy
      - Cell Therapy
      - Vaccinology
      - Research Applications
    - UAE Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - UAE Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others
  - Kuwait
    - Kuwait Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Adenovirus
      - Retrovirus
      - Adeno-Associated Virus (AAV)
      - Lentivirus
      - Plasmids
      - Others
    - Kuwait Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
      - Upstream Manufacturing
        
        Vector Amplification & Expansion
        
        Vector Recovery/Harvesting
      - Downstream Manufacturing
        
        Purification
        
        Fill Finish
    - Kuwait Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Kuwait Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Pharmaceutical and Biopharmaceutical Companies
      - Research Institutes
    - Kuwait Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
      - Cancer
      - Genetic Disorders
      - Infectious Diseases
      - Others

Viral Vectors And Plasmid DNA Manufacturing Market Dynamics

Driver: Robust Pipeline for Gene Therapies and Viral Vector Vaccines

Researchers are working to develop gene-based therapies for treating a wide range of diseases. Although the number of patients receiving gene therapies is less, the future of gene therapy holds great promise as it is expected to revolutionize the treatment regime by targeting the genes responsible for disease pathogenesis. Many universities and institutes have a broad portfolio of gene therapy products in the pipeline. This is expected to boost the gene therapy market growth. For example, the University of Massachusetts Medical School and the University of Utah are conducting some clinical trials aimed at developing and introducing new gene therapies.

Driver: Technological Advancements in Manufacturing Vectors

Over the past few years, the number of vectors manufactured has been suitable only for phase I/II clinical trials. Currently, gene therapy vector manufacturing methods are not suitable for large-scale production. This is one of the major issues faced by market players. Successful clinical trials pertaining to gene therapy-based treatments for common indications, such as Parkinson’s disease, rheumatoid arthritis, and Alzheimer’s disease, have facilitated the large-scale production of gene therapy vectors. This has led to a high demand for new technologies to support large-scale vector production. For example, CEVEC develops solutions to address the aforementioned challenges by developing cell lines that can be grown in suspension in bioreactors of larger working volumes. The company introduced a novel helper-virus-free stable production system for scalable manufacturing of AAV vectors to meet the growing demand for vectors by gene therapy companies.

Restraint: Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy and Viral Vectors

As gene therapy involves modifications or alterations in the set of genes, it has raised several ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic ailment. However, it is anticipated to affect the fetus development significantly. Furthermore, the development and production of gene therapy products involve collaborative efforts from key participants, such as government bodies and companies. Regulatory agencies, such as the FDA, have established several guidance documents demonstrating preclinical & clinical activities as a key to the regulation and review of gene therapy products. However, these guidelines by regulatory bodies of various countries are not uniform. Guidance from the CDC and the National Institutes of Health (NIH) is not well-defined.

What Does This Report Include?

This section will provide insights into the contents included in this viral vectors and plasmid DNA manufacturing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Viral vectors and plasmid DNA manufacturing market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Viral vectors and plasmid DNA manufacturing market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.